We scan new podcasts and send you the top 5 insights daily.
Warma argues that leveraging technology, capital, and people across the US, China, South Korea, and Japan creates more shareholder value while keeping drugs affordable globally. He says this global thinking is often missed by US companies. He applies that lens at ProMIS and Mongoose when considering collaborations and capital.
Western pharma firms strategically license assets from Chinese biotechs while leaving China rights with the local partner. This leverages China's faster, cheaper clinical development, as the partner tests the molecule in new indications, generating valuable data that de-risks the asset for the global firm at no extra cost.
For Korean biotechs, 'thinking globally' often starts regionally. A significant portion of their deals are with other Asian companies. This strategy allows them to combine technologies and create value, using partnerships in markets like Japan as a crucial step before approaching Western markets.
In stark contrast to the often adversarial U.S. perspective, the European biopharma community increasingly views China as a strategic partner. The focus is not on competition but on integration, leveraging China as a "force multiplier" for global drug development and commercialization, highlighting a significant divergence in geopolitical business strategy.
Instead of traditional regional HQs, firms should adopt a "capability-first" model. This involves strategically placing functions where excellence exists: basic science in Japan, clinical scale in China, and biologics in Korea. This creates a more efficient, interconnected global R&D engine, breaking from geography-based silos.
Japan's biotech ecosystem is evolving with a new, successful model for creating cross-border companies. US venture firms are partnering with Japanese academia, combining American management expertise and capital with Japan's strong science and cost-effective R&D to build globally competitive biotechs from their inception.
The firm strategically uses its Basel location to tap into a concentrated pool of talent with deep pharma expertise. However, its deal sourcing is not limited to the local ecosystem. The firm actively in-licenses IP and finds opportunities from around the world, including Japan and other parts of Europe, creating a 'best of both worlds' model.
Beyond being a regional market, South Korea is becoming a key source of novel therapies for Western pharmaceutical giants. Companies like Hanmi are securing major deals, such as their obesity partnership with Genentech/Roche, by developing innovative, potentially first-in-class assets that address high-value global markets.
Despite political pressure to decouple from China, Varistem's CEO defends their collaboration with Chinese firm Genfleet. He argues that leveraging global expertise is essential for bringing drugs to patients faster. The primary mission is to fight cancer, a global problem, which requires prioritizing scientific synergy and patient outcomes over nationalistic concerns and artificial barriers.
Enviva employs a bifurcated global strategy. It leverages China's efficient talent pool and rapid clinical trial system for early discovery and proof-of-concept. It then shifts to the US and Europe for full-scale manufacturing and late-stage clinical development to gain "golden standard" regulatory approval and global market access.
The future biotech landscape is not US vs. China, but a "multipolar" world where savvy companies operate as "hybrid biotechs." They will selectively build bridges, cherry-picking talent, capabilities, and operational models across the US, Europe, and China to accelerate development.